Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received a clinical trial notice for the Class 1 innovative chemical drug KC1101 tablets approved and issued by the State Drug Administration. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received a clinical trial notice for the Class 1 innovative chemical drug KC1101 tablets approved and issued by the State Drug Administration. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.